Tech Tuesday: We’re ready to go above and beyond for you!
Luminex is not only known for the assays based on its proprietary xMAP® Technology, but also exceptional customer service.
With a long history of innovation, Luminex is a company of firsts. The first IVD cleared cystic fibrosis assay, the first respiratory assay, and now the first gastrointestinal panel for the U.S.
The xTAG® GPP (Gastrointestinal Pathogen Panel) is a qualitative molecular multiplex test intended for the simultaneous detection and identification of multiple gastrointestinal pathogens including bacteria, viruses, and parasites in approximately five hours. This is a powerful test for detecting > 90% of gastrointestinal pathogens and identifying potential outbreaks that may have implications in the submission of required pathogens to your state public health laboratory.
Although xTAG GPP is a molecular test that does not result in clinical isolates, this does not exempt a laboratory from reporting results and submitting specimens (clinical material, enrichment broths, or isolates) to their state public health laboratory.
State and local public health authorities have published guidelines for notification of reportable diseases in their jurisdictions including but not limited to Salmonella, Shigella, E. coli O157, Enterotoxigenic E. coli (ETEC) LT/ST, and Shiga-like Toxin producing E. coli (STEC) stx 1/stx 2 to determine necessary measures for verification of results to identify and trace outbreaks.
Laboratories are responsible for following their state or local regulations for submission of clinical material or isolates on positive specimens to their state public health laboratories. The requirements for submission of clinical material, enrichment broth, or isolates for many of these organisms vary by state. It is important that laboratories performing the xTAG GPP assay coordinate with their state public health laboratory to clarify expectations for the submission of this material when these organisms are identified through the performance of a molecular assay.
We are demonstrating our commitment for exceptional service for our customers, our community, and patient care by facilitating communications between labs that adopt this assay and the state public health labs.
Our goal is that labs running this assay can coordinate with their respective local state labs not only on best practices for testing and reporting, but also ensure that results from the GPP assay to feed into the lab faster. This cycle of “faster-better” information flowing into the state labs could lead to faster detection of outbreaks within the U.S.
Products are region specific and may not be approved in some countries/regions. Please contact [email protected] to obtain the appropriate information for your country of residence.